Oncternal Therapeutics Ownership
Oncternal Therapeutics holds 9.23 pct. of its outstanding shares held by insiders and 12.07 pct. owned by third-party entities.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Oncternal |
Oncternal Stock Ownership Analysis
The company has price-to-book ratio of 0.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncternal Therapeutics recorded a loss per share of 11.69. The entity last dividend was issued on the 10th of June 2019. The firm had 1:20 split on the 8th of January 2024. Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Oncternal Therapeutics contact the company at 858 434 1113 or learn more at https://www.oncternal.com.Oncternal Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncternal Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncternal Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncternal Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oncternal Therapeutics Outstanding Bonds
Oncternal Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncternal Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncternal bonds can be classified according to their maturity, which is the date when Oncternal Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
| US68233JBD54 Corp BondUS68233JBD54 | View |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |